XNAS
MDXH
Market cap20mUSD
Oct 07, Last price
0.60USD
1D
-0.02%
1Q
22.43%
IPO
-95.00%
Name
MDxHealth SA
Chart & performance
P/E
—
P/S
0.19
EPS
—
Div yield, %
—
Shrs. gr., 5y
43.16%
Rev. gr., 5y
42.34%
Revenues
108m
+19.80%
Net income
-34m
L-11.95%
CFO
-10m
L-43.78%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
Key people
Ron Kalfus
Chief Financial Officer · since 2019
Christopher Thibodeau
Executive Vice President & U.S. Chief Operations Officer · since 2017
Joseph Sollee
Executive Vice President, Chief Compliance Officer, General Counsel · since 2017
Chief Executive Officer, Executive Director · since 2010
John Bellano
Chief Commercial Officer · since 2019
Michael K. McGarrity
Chief Executive Officer, Director · since 2019
Jan Pensaert
Non-Executive Director · since 2014
Ruth Devenyns
Non-Executive Independent Director · since 2011
Walter M. Narajowski
Non-Executive Independent Director · since 2015
Mark Shaffar
Non-Executive Independent Chairman of the Board · since 2016
Headquarters & legal address
Rue d'Abhooz 31
Herstal, WLG 4040
BE
Herstal, WLG 4040
BE
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||